Thursday, June 19, 2014
Australian researchers are taking a new approach to
attacking brain cancer-raising T cells against antigens from the
cytomegalovirus frequently found in gliomas rather than against tumor targets.1
The approach has shown efficacy in patients, and the next steps include
applying the method to larger cohorts and identifying the best cytomegalovirus
epitopes to be used to activate T cells.
team is starting a Phase II trial of autologous, CMV-specific T cell therapy to
treat primary glioblastoma. The primary endpoints of the trial are the safety
and tolerability of the adoptive transfer of CMV-specific, cytotoxic T cells
and PFS. Secondary endpoints include overall survival.
T. SciBX 7(24); doi:10.1038/scibx.2014.694 Published online June 19, 2014
1. Schuessler, A. et
al. Cancer Res.; published online May 4, 2014;
doi:10.1158/0008-5472.CAN-14-0296 Contact: Rajiv Khanna, QIMR Berghofer
Medical Research Institute, Brisbane, Queensland, Australia e-mail: firstname.lastname@example.org
2. Stupp, R. et al. N.
Engl. J. Med. 352, 987-996 (2005)
3. Stupp, R. et al.
Lancet Oncol. 10, 459-466 (2009)
4. Cinatl, J. et al.
Trends Mol. Med. 10, 19-23 (2004)
5. Michaelis, M. et al.
Med. Microbiol. Immunol. 200, 1-5 (2011)
6. Johnsen, J.I. et al.
Oncotarget 2, 1329-1338 (2011)
7. Prins, R.M. et al.
N. Engl. J. Med. 359, 539-541 (2008)
8. Crough, T. et al.
Immunol. Cell Biol. 90, 872-880 (2012)
AND INSTITUTIONS MENTIONED
Karolinska Institute, Stockholm, Sweden
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
University of California, Los Angeles, Calif.
University of Florida College of Medicine, Gainesville, Fla.